Merck
  • Home
  • Search Results
  • YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model.

YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model.

Oncotarget (2015-10-16)
Tsion Zewdu Minas, Jenny Han, Tahereh Javaheri, Sung-Hyeok Hong, Michaela Schlederer, Yasemin Saygideğer-Kont, Haydar Çelik, Kristina M Mueller, Idil Temel, Metin Özdemirli, Heinrich Kovar, Hayriye Verda Erkizan, Jeffrey Toretsky, Lukas Kenner, Richard Moriggl, Aykut Üren
ABSTRACT

Ewing sarcoma is an aggressive tumor of bone and soft tissue affecting predominantly children and young adults. Tumor-specific chromosomal translocations create EWS-FLI1 and similar aberrant ETS fusion proteins that drive sarcoma development in patients. ETS family fusion proteins and over-expressed ETS proteins are also found in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients. Transgenic expression of EWS-FLI1 in mice promotes high penetrance erythroid leukemia with dense hepatic and splenic infiltrations. We identified a small molecule, YK-4-279, that directly binds to EWS-FLI1 and inhibits its oncogenic activity in Ewing sarcoma cell lines and xenograft mouse models. Herein, we tested in vivo therapeutic efficacy and potential side effects of YK-4-279 in the transgenic mouse model with EWS-FLI1 induced leukemia. A two-week course of treatment with YK-4-279 significantly reduced white blood cell count, nucleated erythroblasts in the peripheral blood, splenomegaly, and hepatomegaly of erythroleukemic mice. YK-4-279 inhibited EWS-FLI1 target gene expression in neoplastic cells. Treated animals showed significantly better overall survival compared to control mice that rapidly succumbed to leukemia. YK-4-279 treated mice did not show overt toxicity in liver, spleen, or bone marrow. In conclusion, this in vivo study highlights the efficacy of YK-4-279 to treat EWS-FLI1 expressing neoplasms and support its therapeutic potential for patients with Ewing sarcoma and other ETS-driven malignancies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
塩化ナトリウム, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
ビオチン, ≥99% (HPLC), lyophilized powder
Sigma-Aldrich
HEPES, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
塩化ナトリウム, for molecular biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
塩化ナトリウム 溶液, 5 M in H2O, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
エチレンジアミン四酢酸, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
塩化ナトリウム 溶液, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
フェニルメチルスルホニルフルオリド, ≥98.5% (GC)
Sigma-Aldrich
塩化ナトリウム, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
塩化ナトリウム 溶液, 5 M
Sigma-Aldrich
フッ化ナトリウム, ACS reagent, ≥99%
Sigma-Aldrich
エチレンジアミン四酢酸, BioUltra, anhydrous, ≥99% (titration)
Sigma-Aldrich
HEPES緩衝液, 1 M in H2O
Sigma-Aldrich
エチレンジアミン四酢酸 溶液, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
塩化ナトリウム, meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%
Sigma-Aldrich
塩化ナトリウム, JIS special grade, ≥99.5%
SAFC
HEPES
Sigma-Aldrich
ピロリン酸ナトリウム 四塩基性, ≥95%
Sigma-Aldrich
塩化ナトリウム 溶液, BioUltra, for molecular biology, ~5 M in H2O
Sigma-Aldrich
塩化ナトリウム, BioUltra, for molecular biology, ≥99.5% (AT)
Sigma-Aldrich
エチレンジアミン四酢酸, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
エチレンジアミン四酢酸, purified grade, ≥98.5%, powder
Sigma-Aldrich
塩化ナトリウム 溶液, 0.85%
Sigma-Aldrich
HEPES, BioUltra, for molecular biology, ≥99.5% (T)
Sigma-Aldrich
フェニルメチルスルホニルフルオリド, ≥99.0% (T)
Sigma-Aldrich
HEPES, BioXtra, pH 5.0-6.5 (1 M in H2O), ≥99.5% (titration)
Sigma-Aldrich
フッ化ナトリウム, BioXtra, ≥99%
Sigma-Aldrich
エチレンジアミン四酢酸, 99.995% trace metals basis
SAFC
HEPES